AI Article Synopsis
- The variety of biological therapies for inflammatory bowel disease (IBD) has significantly increased, with the number available doubling in the last decade and new treatments like interleukin 23p19 inhibitors being introduced.* -
- Properly positioning these advanced therapies based on factors such as clinical situation, effectiveness, and safety is essential for delivering personalized IBD treatment.* -
- This publication summarizes recent literature and expert insights to help integrate comparative efficacy data and patient demographics into clinical practice for better decision-making regarding biological therapies.*
Article Abstract
The number of available biological therapies have doubled over the last 10 years and the arrival of novel molecules (interleukin 23p19 inhibitors) is ongoing alongside the development of small molecules. As a result of this vast landscape of treatment, positioning advanced therapies (according to clinical situation, efficacy and safety) is of paramount importance to providing personalized, appropriate IBD treatment. In this publication the recent available literature is summarized for practical integration into clinical practice including comparative efficacy data, patient and disease demographics. We refer to recent publications and expert opinion in order to facilitate the decision making process of positioning biologicals IBD treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092374 | PMC |
| http://dx.doi.org/10.1016/j.crphar.2022.100104 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!